Guggenheim analyst Vamil Divan reiterated a Buy rating and $36.00 price target on Pfizer (NYSE: PFE).The analyst commented: "We are ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments